CellaVision AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000683484
SEK
157.20
-3.2 (-2.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About CellaVision AB stock-summary
stock-summary
CellaVision AB
Pharmaceuticals & Biotechnology
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Company Coordinates stock-summary
Company Details
Mobilvagen 12 , LUND None : 223 62
stock-summary
Tel: 46 46 460160046 46 4601652
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Soren Mellstig
Independent Chairman of the Board
Mr. Christer Fahraeus
Director
Ms. Asa Hedin
Independent Director
Ms. Anna Malm Bernsten
Independent Director
Mr. Niklas Prager
Independent Director
Mr. Juergen Riedl
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
191 Million
(Quarterly Results - Jun 2025)
Net Profit:
38 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 3,826 Million (Small Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.01%

stock-summary
Debt Equity

-0.15

stock-summary
Return on Equity

17.78%

stock-summary
Price to Book

4.49